Page 2447

(6) medical history, including any current illness, that the pharmacist considers significant;

(7) allergies;

(8) drug reactions;

(9) medications currently used;

(10) medical devices currently used;

(11) the pharmacist’s comments relating to the recipient’s drug therapy. (c) As part of the prospective drug use review under this section, a pharmacist shall review the prescription, either manually or by computer, against the following criteria:

(1) therapeutic duplication;

(2) drug-disease contraindications;

(3) interactions between the prescription and other drugs being taken;

(4) incorrect dose or duration;

(5) possible allergic reactions;

(6) potential for clinical abuse or misuse. (d) To complete the prospective drug use review under this section, a pharmacist shall provide the recipient with recipient counseling, as required by 12 AAC 52.585, and shall document in a permanent record the recipient’s acceptance or refusal of counseling. (e) In accordance with 42 C.F.R. 456.716, the department establishes a drug use review committee to help the department comply with federal drug use review requirements. The drug use review committee will help the department

(1) implement prospective drug use review in accordance with 42 C.F.R. 456.705, including recommending changes to the pharmacist review practices described in this section;

(2) implement retrospective drug use review in accordance with 42 C.F.R. 42 C.F.R. 456.709, including periodic examination of past drug prescription practices;

(3) assess drug use data in accordance with 42 C.F.R. 456.703;

(4) implement an educational program in accordance with 42 C.F.R. 456.711, including recommending changes in prescribing or dispensing practices when appropriate to meet the intent of this section; and

(5) prepare and submit an annual report to the United States Department of Health and Human Services in accordance with 42 C.F.R. 456.712.